Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout
Five months after MyoKardia $MYOK swept its late-stage pivotal on its lead heart drug — highlighting its success with a precision med approach to cardiology — Bristol Myers Squibb is stepping up with a $13.1 billion buyout tied to a big premium.
Bristol Myers is paying $225 a share — a 61% premium — to get its hands on the cardio player, highlighting its interest in mavacamten, where execs see a first-in-class role treating obstructive hypertrophic cardiomyopathy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.